A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)

Conditions: Moderate to Severe Rheumatoid Arthritis Interventions: Drug: Burfiralimab; Drug: SOC (Standard of care); Drug: Placebo Sponsors: ImmuneMed, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials